Methicillin-resistant Staphylococcus aureus

Andie S. Lee, Herminia De Lencastre, Javier Garau, Jan Kluytmans, Surbhi Malhotra-Kumar, Andreas Peschel, Stephan Harbarth

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Since the 1960s, methicillin-resistant Staphylococcus aureus (MRSA) has emerged, disseminated globally and become a leading cause of bacterial infections in both health-care and community settings. However, there is marked geographical variation in MRSA burden owing to several factors, including differences in local infection control practices and pathogen-specific characteristics of the circulating clones. Different MRSA clones have resulted from the independent acquisition of staphylococcal cassette chromosome mec (SCCmec), which contains genes encoding proteins that render the bacterium resistant to most β-lactam antibiotics (such as methicillin), by several S. aureus clones. The success of MRSA is a consequence of the extensive arsenal of virulence factors produced by S. aureus combined with β-lactam resistance and, for most clones, resistance to other antibiotic classes. Clinical manifestations of MRSA range from asymptomatic colonization of the nasal mucosa to mild skin and soft tissue infections to fulminant invasive disease with high mortality. Although treatment options for MRSA are limited, several new antimicrobials are under development. An understanding of colonization dynamics, routes of transmission, risk factors for progression to infection and conditions that promote the emergence of resistance will enable optimization of strategies to effectively control MRSA. Vaccine candidates are also under development and could become an effective prevention measure.

Original languageEnglish
Article number18033
JournalNature Reviews Disease Primers
Volume4
DOIs
Publication statusPublished - 31 May 2018

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Clone Cells
Lactams
Staphylococcus aureus
Anti-Bacterial Agents
Soft Tissue Infections
Methicillin
Nasal Mucosa
Virulence Factors
Infection Control
Bacterial Infections
Vaccines
Chromosomes
Bacteria
Delivery of Health Care
Skin
Mortality
Infection
Proteins

Cite this

Lee, A. S., De Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018). Methicillin-resistant Staphylococcus aureus. Nature Reviews Disease Primers, 4, [18033]. https://doi.org/10.1038/nrdp.2018.33
Lee, Andie S. ; De Lencastre, Herminia ; Garau, Javier ; Kluytmans, Jan ; Malhotra-Kumar, Surbhi ; Peschel, Andreas ; Harbarth, Stephan. / Methicillin-resistant Staphylococcus aureus. In: Nature Reviews Disease Primers. 2018 ; Vol. 4.
@article{d4c6c3842fd04c3f889ada85d0adf264,
title = "Methicillin-resistant Staphylococcus aureus",
abstract = "Since the 1960s, methicillin-resistant Staphylococcus aureus (MRSA) has emerged, disseminated globally and become a leading cause of bacterial infections in both health-care and community settings. However, there is marked geographical variation in MRSA burden owing to several factors, including differences in local infection control practices and pathogen-specific characteristics of the circulating clones. Different MRSA clones have resulted from the independent acquisition of staphylococcal cassette chromosome mec (SCCmec), which contains genes encoding proteins that render the bacterium resistant to most β-lactam antibiotics (such as methicillin), by several S. aureus clones. The success of MRSA is a consequence of the extensive arsenal of virulence factors produced by S. aureus combined with β-lactam resistance and, for most clones, resistance to other antibiotic classes. Clinical manifestations of MRSA range from asymptomatic colonization of the nasal mucosa to mild skin and soft tissue infections to fulminant invasive disease with high mortality. Although treatment options for MRSA are limited, several new antimicrobials are under development. An understanding of colonization dynamics, routes of transmission, risk factors for progression to infection and conditions that promote the emergence of resistance will enable optimization of strategies to effectively control MRSA. Vaccine candidates are also under development and could become an effective prevention measure.",
author = "Lee, {Andie S.} and {De Lencastre}, Herminia and Javier Garau and Jan Kluytmans and Surbhi Malhotra-Kumar and Andreas Peschel and Stephan Harbarth",
year = "2018",
month = "5",
day = "31",
doi = "10.1038/nrdp.2018.33",
language = "English",
volume = "4",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Research",

}

Lee, AS, De Lencastre, H, Garau, J, Kluytmans, J, Malhotra-Kumar, S, Peschel, A & Harbarth, S 2018, 'Methicillin-resistant Staphylococcus aureus', Nature Reviews Disease Primers, vol. 4, 18033. https://doi.org/10.1038/nrdp.2018.33

Methicillin-resistant Staphylococcus aureus. / Lee, Andie S.; De Lencastre, Herminia; Garau, Javier; Kluytmans, Jan; Malhotra-Kumar, Surbhi; Peschel, Andreas; Harbarth, Stephan.

In: Nature Reviews Disease Primers, Vol. 4, 18033, 31.05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Methicillin-resistant Staphylococcus aureus

AU - Lee, Andie S.

AU - De Lencastre, Herminia

AU - Garau, Javier

AU - Kluytmans, Jan

AU - Malhotra-Kumar, Surbhi

AU - Peschel, Andreas

AU - Harbarth, Stephan

PY - 2018/5/31

Y1 - 2018/5/31

N2 - Since the 1960s, methicillin-resistant Staphylococcus aureus (MRSA) has emerged, disseminated globally and become a leading cause of bacterial infections in both health-care and community settings. However, there is marked geographical variation in MRSA burden owing to several factors, including differences in local infection control practices and pathogen-specific characteristics of the circulating clones. Different MRSA clones have resulted from the independent acquisition of staphylococcal cassette chromosome mec (SCCmec), which contains genes encoding proteins that render the bacterium resistant to most β-lactam antibiotics (such as methicillin), by several S. aureus clones. The success of MRSA is a consequence of the extensive arsenal of virulence factors produced by S. aureus combined with β-lactam resistance and, for most clones, resistance to other antibiotic classes. Clinical manifestations of MRSA range from asymptomatic colonization of the nasal mucosa to mild skin and soft tissue infections to fulminant invasive disease with high mortality. Although treatment options for MRSA are limited, several new antimicrobials are under development. An understanding of colonization dynamics, routes of transmission, risk factors for progression to infection and conditions that promote the emergence of resistance will enable optimization of strategies to effectively control MRSA. Vaccine candidates are also under development and could become an effective prevention measure.

AB - Since the 1960s, methicillin-resistant Staphylococcus aureus (MRSA) has emerged, disseminated globally and become a leading cause of bacterial infections in both health-care and community settings. However, there is marked geographical variation in MRSA burden owing to several factors, including differences in local infection control practices and pathogen-specific characteristics of the circulating clones. Different MRSA clones have resulted from the independent acquisition of staphylococcal cassette chromosome mec (SCCmec), which contains genes encoding proteins that render the bacterium resistant to most β-lactam antibiotics (such as methicillin), by several S. aureus clones. The success of MRSA is a consequence of the extensive arsenal of virulence factors produced by S. aureus combined with β-lactam resistance and, for most clones, resistance to other antibiotic classes. Clinical manifestations of MRSA range from asymptomatic colonization of the nasal mucosa to mild skin and soft tissue infections to fulminant invasive disease with high mortality. Although treatment options for MRSA are limited, several new antimicrobials are under development. An understanding of colonization dynamics, routes of transmission, risk factors for progression to infection and conditions that promote the emergence of resistance will enable optimization of strategies to effectively control MRSA. Vaccine candidates are also under development and could become an effective prevention measure.

UR - http://www.scopus.com/inward/record.url?scp=85047933358&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2018.33

DO - 10.1038/nrdp.2018.33

M3 - Article

VL - 4

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 18033

ER -

Lee AS, De Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A et al. Methicillin-resistant Staphylococcus aureus. Nature Reviews Disease Primers. 2018 May 31;4. 18033. https://doi.org/10.1038/nrdp.2018.33